Stock listing

Shanghai:603387 Getein Biotech, Inc. (基蛋生物) 股价

Follow Getein Biotech, Inc. into a list and get an email when it puts out news.

Share price · SSE:603387

¥7.99 CNY -0.28 (-3.4%)

Close on Nov 20, 2026

Past year -5.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥7.87 – ¥8.09 CNYNov 20, 2026
Volume
7.68M sharesNov 20, 2026
Market cap
¥4.05B CNYAt the close on Nov 20, 2026 · price × 507.2M shares outstanding
52-week range
¥7.37 – ¥11.42 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥82.05M CNYMedian day 8.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Getein Biotech, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:603387 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥7.99-0.28-3.4%¥8.02¥8.09¥7.877,680,589
¥8.27+0.01+0.1%¥8.29¥8.31¥8.135,065,720
¥8.26+0.06+0.7%¥8.17¥8.30¥8.105,579,900
¥8.20-0.04-0.5%¥8.20¥8.30¥8.134,819,000
¥8.24-0.31-3.6%¥8.51¥8.55¥8.2111,332,396
¥8.55+0.04+0.5%¥8.52¥8.60¥8.467,470,734
¥8.51+0.01+0.1%¥8.49¥8.51¥8.445,553,996
¥8.50+0.05+0.6%¥8.50¥8.56¥8.475,899,256
¥8.45-0.06-0.7%¥8.56¥8.65¥8.435,999,320
¥8.51-0.21-2.4%¥8.57¥8.68¥8.507,560,092
¥8.72+0.12+1.4%¥8.56¥8.74¥8.559,682,080
¥8.60+0.14+1.7%¥8.45¥8.63¥8.409,170,016
¥8.46-0.01-0.1%¥8.46¥8.57¥8.348,150,236
¥8.47+0.02+0.2%¥8.48¥8.60¥8.3211,411,084
¥8.45-0.09-1.1%¥8.51¥8.83¥8.339,384,452
¥8.54-0.17-2.0%¥8.63¥8.75¥8.517,258,153
¥8.71+0.06+0.7%¥8.54¥8.77¥8.3710,989,965
¥8.65-0.47-5.2%¥9.15¥9.22¥8.629,373,585
¥9.12+0.21+2.4%¥8.90¥9.25¥8.838,490,677
¥8.91+0.06+0.7%¥8.82¥8.95¥8.538,138,200
¥8.85-0.29-3.2%¥9.21¥9.21¥8.837,514,976
¥9.14-0.01-0.1%¥9.21¥9.44¥9.117,120,057
¥9.15+0.17+1.9%¥9.01¥9.21¥8.946,661,439
¥8.98-0.19-2.1%¥9.11¥9.28¥8.828,798,100
¥9.17-0.16-1.7%¥9.38¥9.69¥9.068,529,389
¥9.33-0.16-1.7%¥9.25¥9.48¥9.197,296,983
¥9.49-0.15-1.6%¥9.76¥9.76¥9.385,855,183
¥9.64-0.12-1.2%¥9.71¥9.71¥9.408,884,492
¥9.76-0.29-2.9%¥10.03¥10.05¥9.768,576,008
¥10.05-0.11-1.1%¥10.05¥10.10¥9.6813,507,548
¥10.16+0.15+1.5%¥10.10¥10.23¥9.9113,157,760
¥10.01+0.20+2.0%¥9.81¥10.10¥9.7510,190,729
¥9.81-0.10-1.0%¥9.91¥9.97¥9.747,433,074
¥9.91+0.09+0.9%¥9.87¥10.11¥9.849,617,354
¥9.82-0.13-1.3%¥9.85¥10.05¥9.818,887,300
¥9.95-0.14-1.4%¥10.00¥10.12¥9.9011,017,375
¥10.09+0.15+1.5%¥9.94¥10.25¥9.8019,290,213
¥9.94+0.52+5.5%¥9.48¥9.98¥9.4318,305,978
¥9.42-0.06-0.6%¥9.35¥9.59¥9.309,810,621
¥9.48+0.27+2.9%¥9.27¥9.49¥9.2110,606,796
¥9.21+0.13+1.4%¥9.05¥9.23¥9.034,372,942
¥9.08-0.14-1.5%¥9.16¥9.22¥9.034,976,560
¥9.22+0.13+1.4%¥9.01¥9.28¥9.014,497,649
¥9.09-0.14-1.5%¥9.18¥9.24¥8.995,942,236
¥9.23-0.24-2.5%¥9.48¥9.48¥9.195,157,089
¥9.47+0.02+0.2%¥9.39¥9.54¥9.286,817,135
¥9.45+0.23+2.5%¥9.25¥9.48¥9.177,980,550
¥9.22-0.05-0.5%¥9.22¥9.39¥9.175,222,620
¥9.27-0.03-0.3%¥9.29¥9.42¥9.196,309,387
¥9.30-0.09-1.0%¥9.42¥9.46¥9.276,005,519
¥9.39-0.13-1.4%¥9.48¥9.51¥9.335,996,736
¥9.52+0.20+2.1%¥9.30¥9.57¥9.2610,900,912
¥9.32-0.01-0.1%¥9.27¥9.35¥9.207,592,959
¥9.33-0.08-0.9%¥9.53¥9.54¥9.309,214,544
¥9.41-0.12-1.3%¥9.55¥9.79¥9.3314,309,597
¥9.53+0.19+2.0%¥9.33¥9.92¥9.3315,064,899
¥9.34+0.16+1.7%¥9.13¥9.35¥9.098,155,160
¥9.18-0.24-2.5%¥9.38¥9.38¥9.0811,107,073
¥9.42-0.23-2.4%¥9.51¥9.56¥9.2313,284,135
¥9.65+0.40+4.3%¥9.27¥9.72¥9.2719,612,188

Splits

4 splits since 2018 · SSE:603387 · every price before a split is adjusted for it

DayRatioWhat
7-for-5Split
7-for-5Split
7-for-5Split
7-for-5Split
Ticker
Shanghai:603387
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Getein Biotech, Inc. news

Getein Biotech, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
24 in the last 12 months · 51 in all · newest Nov 4, 2026 · oldest 2024

Valuation

P/E 13.8× against a median of 69.9×: the lowest of 5 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥2.39B CNY
P/E
13.8×
EV/sales
2.1×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.4×
Gross margin
69.9%
Operating margin
27.6%
Net margin
26.3%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Getein Biotech, Inc. Class A · SSE:603387US$608.2MUS$358.4M13.8×2.1×n/a1.4×26.3%0.0×n/a
Maccura Biotechnology Co., Ltd. Class A · SZSE:300463US$722.4MUS$677.6Mn/a2.1×n/a0.8×−1.5%0.1×n/a
R&G PharmaStudies Co., Ltd. Class A · SZSE:301333US$706.0MUS$456.1M40.4×3.2×n/a2.4×12.2%0.0×n/a
OmniAb, Inc. · NASDAQ:OABIUS$679.7MUS$615.5Mn/a15.3×n/a2.7×−108.1%0.0×1.29
SD Biosensor, Inc. · KRX:137310US$655.8MUS$520.0Mn/a0.9×11.5×0.4×−98.8%0.1×n/a
PharmaResources (Shanghai) Co., Ltd Class A · SZSE:301230US$641.2MUS$600.8M149×5.5×n/a4.2×4.0%0.0×n/a
QuidelOrtho Corporation · NASDAQ:QDELUS$570.9MUS$828.9Mn/a0.3×2.5×0.3×−14.2%0.2×2.56
Shanghai Obio Technology (Group) Corp., Ltd. Class A · SSE:688238US$542.6MUS$548.0Mn/a12.4×n/a2.9×−74.6%0.5×n/a
Frontage Holdings Corp. · HKEX:1521US$539.7MUS$643.1M79.5×2.5×12.6×1.5×2.6%0.4×n/a
Boji Medical Technology Co., Ltd Class A · SZSE:300404US$524.0MUS$473.9M60.3×3.1×n/a3.2×5.7%0.0×n/a
Myriad Genetics, Inc. · NASDAQ:MYGNUS$523.7MUS$537.7Mn/a0.7×n/a1.9×−16.1%0.5×0.67
Median of the othersUS$606.0MUS$574.4M69.9×2.8×11.5×2.1×−7.9%0.1×1.29

Events

QuarterResultsShare move
Q1 2023Apr 27, 2023+10.6%
Q3 2022Oct 27, 2022−1.0%
Q2 2022Aug 24, 2022−6.6%
Q1 2022Apr 27, 2022 · Before open+6.6%
Quarter to Sep 30, 2021Oct 29, 2021+2.0%
Quarter to Jun 30, 2021Aug 17, 2021 · Before open−0.9%
Quarter to Mar 31, 2021Apr 27, 2021 · After close−10.0%
Quarter to Dec 31, 2020Mar 3, 2021 · Before open+8.1%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.05B1.16B1.37B1.82B1.40B1.12B968.2M686.2M488.6M369.1M
Cost of revenue317.7M374.4M479.7M671.6M485.4M414.4M264.9M144.1M88.6M69.4M
Gross profit734.0M790.4M889.5M1.15B916.3M708.9M703.3M542.2M400.0M299.7M
Research and development157.4M181.2M218.0M223.2M163.4M119.1M104.7M80.6M54.0M39.3M
Selling, general and administrative79.6M95.7M106.8M103.9M90.6M75.9M63.2M54.9M37.7M68.6M
Operating income257.0M258.1M306.6M563.3M452.8M378.0M398.9M282.8M223.3M152.6M
Depreciation and amortization85.4M93.6M93.1M70.4M49.4M35.9M27.9M24.8M21.0M15.6M
EBITDA342.4M351.7M399.7M633.6M502.2M413.9M426.9M307.5M244.4M168.3M
Interest expense12.1M15.4M17.5M17.1M16.0M7.17M1.65M120.9K1.49M55.9K
Income before tax227.7M253.4M304.9M560.0M451.6M374.0M396.0M287.3M224.0M161.7M
Income tax23.6M20.9M56.0M39.6M43.7M46.0M36.6M30.2M23.3M
Net income220.7M223.6M279.8M498.9M399.0M304.7M339.7M249.6M194.0M138.4M
Earnings per share, basic0.440.440.550.980.780.600.660.490.450.36

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents313.9M351.6M484.3M646.2M968.9M801.5M659.5M145.4M301.0M26.3M
Short-term investments912.6M648.9M451.9M511.1M612.7M594.9M467.4M634.1M167.1M
Receivables359.5M407.8M478.6M496.9M446.0M472.0M247.8M79.3M33.4M31.9M
Inventory183.8M194.5M229.7M269.4M252.3M212.0M160.7M126.4M62.3M49.1M
Current assets2.30B1.86B2.15B2.40B2.37B2.12B1.57B1.28B1.05B279.2M
Property, plant and equipment556.5M452.2M369.6M296.8M231.4M174.9M122.5M
Goodwill12.0M309.7K26.1M26.1M26.1M26.1M309.7K309.7K309.7K
Total assets3.76B3.71B3.77B3.68B3.14B2.70B2.01B1.57B1.27B434.1M
Accounts payable190.2M145.9M129.1M121.4M121.1M118.3M67.0M26.8M11.0M9.66M
Current liabilities855.2M940.0M977.9M958.1M813.5M656.6M316.9M180.0M111.7M85.3M
Long-term debt3.00M27.8M20.0M
Total debt577.2M644.0M591.0M496.5M384.8M95.0M31.2M
Total liabilities896.6M986.4M1.03B1.01B863.9M695.9M326.0M187.2M118.9M91.1M
Shareholders' equity2.75B2.62B2.56B2.48B2.11B1.84B1.62B1.35B1.14B340.1M
Shares outstanding507.2M508.3M508.7M509.1M511.5M507.9M512.1M509.6M432.7M379.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations392.6M423.0M333.2M483.0M432.4M185.5M225.7M187.1M191.9M155.9M
Capital spending-150.6M-156.4M-258.1M-217.4M-179.6M-113.5M-124.8M-110.7M-61.4M-39.3M
Free cash flow242.0M266.6M75.1M265.5M252.8M71.9M100.9M76.4M130.6M116.6M
Cash from investing-348.1M-356.8M-760.4M-254.6M-238.7M261.8M-345.5M-519.3M-82.3M
Cash from financing-213.7M-145.9M-45.9M-28.9M200.0M25.9M-1.51M602.8M-59.2M
Dividends paid-103.2M-111.0M-219.4M-123.2M-93.2M-104.2M-76.3M-59.8M-68.2M-59.3M
Share buybacks-50.4M-541.8K-535.2K-654.3K
Change in cash-41.1M-132.9M-157.8M-304.2M147.8M140.7M514.2M-158.6M274.8M14.8M

Open Financials

Filings

FilingDateTypeFiled with
(603387)"Getein Biotech, Inc"Announcement on Outline of the Q3 2026 Online Performance BriefingNov 4, 2026ResultsShanghai Stock Exchange
(603387)"Getein Biotech, Inc."Announcement on Progress in Repurchasing Shares through Call AuctionNov 4, 2026Other filingsShanghai Stock Exchange
(603387)"Getein Biotech, Inc"Report for Q3 2026Oct 28, 2026Quarterly reportShanghai Stock Exchange
(603387)"Getein Biotech, Inc"Announcement on Convening the Q3 2026 Online Performance BriefingOct 28, 2026Meeting noticeShanghai Stock Exchange
(603387)"Getein Biotech, Inc."Announcement on Progress in Repurchasing Shares through Call AuctionOct 10, 2026Other filingsShanghai Stock Exchange
"Getein Biotech, Inc."Announcement on Outline of the 2026 Semi-annual Online Performance BriefingSep 15, 2026Meeting noticeShanghai Stock Exchange
"Getein Biotech, Inc."Announcement on Adjustment of Upper Limit of Repurchase Price Following Implementation of Dividend Distribution for the First Half of 2026Sep 11, 2026DividendShanghai Stock Exchange
"Getein Biotech, Inc."Announcement on Obtaining a Commitment Letter for a Special Loan for Share Repurchase from a Financial InstitutionAug 31, 2026FinancingShanghai Stock Exchange
"Getein Biotech, Inc."Announcement on Resolutions of the 14th Meeting of the 4th Board of DirectorsAug 26, 2026Meeting outcomeShanghai Stock Exchange
"Getein Biotech, Inc."Announcement on Progress in Repurchasing Shares through Call AuctionAug 3, 2026Other filingsShanghai Stock Exchange
All 51 filings
FilingDateTypeFiled with
"Getein Biotech, Inc."Announcement on the Progress of Implementing the "Settlement Agreement" and Transferring Equity Interests in a Controlled SubsidiaryJul 16, 2026Operations updateShanghai Stock Exchange
"Getein Biotech, Inc"Announcement on Expected Increase in Semi-annual Performance for 2026Jul 14, 2026GuidanceShanghai Stock Exchange
"Getein Biotech, Inc"Announcement on the Shareholdings of the Top Ten Shareholders and the Top Ten Holders of Unrestricted Shares Prior to the Share RepurchaseJul 8, 2026Other filingsShanghai Stock Exchange
"Getein Biotech, Inc"Announcement on the Initial Repurchase of Shares through Call AuctionJul 7, 2026Treasury share statusShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2025Jun 11, 2026DividendShanghai Stock Exchange
Announcement on Outline of the Online Performance Briefing for 2025 and Q1 2026May 27, 2026Meeting noticeShanghai Stock Exchange
Announcement on Resolutions of the 2025 Annual General MeetingMay 22, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Using Self-owned Idle Funds for Investment and Wealth ManagementApr 29, 2026Other filingsShanghai Stock Exchange
and Transfer of Equity in the Holding SubsidiaryApr 24, 2026Acquisition or disposalShanghai Stock Exchange
Announcement on Appointing the Secretary of the Board of DirectorsApr 13, 2026Management or board changeShanghai Stock Exchange
Announcement on Adjustment of Partial Members of the Special Committee of the Board of DirectorsApr 10, 2026Management or board changeShanghai Stock Exchange
Announcement on Resignation of the Securities Affairs RepresentativeMar 27, 2026Management or board changeShanghai Stock Exchange
Announcement on Resignation of Secretary of Board of DirectorsMar 20, 2026Management or board changeShanghai Stock Exchange
Announcement on Abnormal Fluctuations in Stock TradingMar 18, 2026Other filingsShanghai Stock Exchange
Announcement on Outline of the Q3 2025 Online Performance BriefingNov 21, 2025Meeting noticeShanghai Stock Exchange
Report for Q3 2025Oct 30, 2025Quarterly reportShanghai Stock Exchange
Announcement on Completing Industrial and Commercial Change Registration and Filing and Obtaining the Business LicenseSep 29, 2025Other filingsShanghai Stock Exchange
Announcement on Progress in Litigation Involving the CompanySep 18, 2025Legal or regulatory actionShanghai Stock Exchange
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025Sep 15, 2025Meeting noticeShanghai Stock Exchange
Announcement on Outline of the 2025 Semi-annual Performance Online BriefingSep 10, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Semi-annual Dividend Distribution for 2025Sep 8, 2025DividendShanghai Stock Exchange
Announcement on Resolutions of the 7th Meeting of the 4th Board of DirectorsAug 29, 2025Other filingsShanghai Stock Exchange
Announcement on Result of Shareholding Reduction by ShareholderAug 15, 2025Other filingsShanghai Stock Exchange
Announcement on Progress of Litigation Involving the CompanyJul 22, 2025Legal or regulatory actionShanghai Stock Exchange
Announcement on Investment in Construction of an Intelligent Production and R&D BaseJul 4, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2024Jun 10, 2025DividendShanghai Stock Exchange
Announcement on Outline of the Online 2024 Annual and Q1 2025 Performance BriefingMay 27, 2025Other filingsShanghai Stock Exchange
Announcement on Resolution of the 2024 Annual General MeetingMay 22, 2025Meeting noticeShanghai Stock Exchange
Announcement on Share Reduction Plan for ShareholdersMay 14, 2025Other filingsShanghai Stock Exchange
Announcement on the Interim Dividend Distribution Arrangement in 2025May 13, 2025DividendShanghai Stock Exchange
Announcement on Changes in Accounting PoliciesApr 29, 2025Other filingsShanghai Stock Exchange
Announcement on Result of Litigation Involving the CompanyFeb 26, 2025Legal or regulatory actionShanghai Stock Exchange
Announcement on Litigation Involving the CompanyDec 24, 2024Legal or regulatory actionShanghai Stock Exchange
Announcement on Outline of the Q3 2024 Online Performance BriefingNov 12, 2024Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 4th Meeting of the 4th Board of SupervisorsOct 30, 2024Other filingsShanghai Stock Exchange
Announcement on Termination of Listing on National Equities Exchange and Quotations by Holding Subsidiary Wuhan King Diagnostic Technology Co., Ltd.Oct 24, 2024Other filingsShanghai Stock Exchange
Announcement on Progress of the Company's Involvement in LitigationOct 18, 2024Legal or regulatory actionShanghai Stock Exchange
Announcement on the Convening of Online Briefing on 2024 Semi-annual PerformanceSep 12, 2024Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Medical Device Registration Certificate for Relevant ProductSep 11, 2024Other filingsShanghai Stock Exchange
Announcement on Implementation of Semi-annual Dividend Distribution in 2024Sep 10, 2024DividendShanghai Stock Exchange
Announcement on Resolutions of the 3rd Meeting of the 4th Board of DirectorsAug 30, 2024Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Getein Biotech, Inc. Class A’s releases

Common shares
507,153,517
Fully diluted
507,153,517

Fully diluted

LineShares
Common shares507,153,517

Share count over time

CountShares
Nov 22, 2026507,153,517

Open Cap table

Shareholders

HolderSharesValueAs of
State Street(R) SPDR(R) Portfolio Emerging Markets ETF642KUS$715KJun 30, 2026
Acadian Emerging Markets Portfolio641KUS$845KJul 31, 2026
Emerging Markets Core Equity 2 Portfolio198KUS$261KJul 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF80,228US$89,352Jun 30, 2026
Dimensional Emerging Core Equity Market ETF52,900US$69,715Jul 31, 2026
The Emerging Markets Small Cap Series45,600US$60,108Jul 31, 2026
Dimensional Emerging Markets Value Fund36,800US$48,508Jul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF35,600US$46,916Jul 31, 2026
Dimensional Emerging Markets Value ETF33,800US$44,543Jul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF31,000US$40,854Jul 31, 2026
All 14 holders
HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Emerging Asia Pacific ETF27,128US$30,213Jun 30, 2026
Emerging Markets Social Core Equity Portfolio16,600US$21,881Jul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio9,212US$12,143Jul 31, 2026
World ex U.S. Core Equity Portfolio8,036US$10,593Jul 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Getein Biotech, Inc.